CLSA Wire

CLSA President & CEO Mike Guerra pens an op-ed in Morning Consult regarding the dangers of policymakers utilizing foreign price controls to lower drug costs. With growing bipartisan support for these schemes, CLSA is working to educate policymakers that importing price controls will do little to lessen the financial burden for patients. Rather, these short-sighted proposals will hinder access to needed treatments and discourage medical innovation in California.

On behalf of our membership and California’s statewide life sciences community – a sector which employs over 311,000 Californians – California Life Sciences Association (CLSA) welcomes Senator Lena Gonzalez (D-Long Beach). We look forward to working with Senator Gonzalez and her team to advance policies that improve patient health and bring positive change for California patients and their families.

While fewer bills directly targeting the biopharmaceutical industry were introduced this year, which was likely due in large part to Governor Newsom’s executive order on state prescription purchasing, CLSA strongly supported several bills that reached the Governor’s desk and helped prevent a number of bills of concern from reaching his desk.

CLSA Board Member Wendye Robbins, MD, President & CEO of Blade Therapeutics, pens an op-ed in the San Francisco Chronicle, urging the Legislature to make key changes to Assembly Bill 824, priority legislation for CLSA that seeks to prohibit generic drug manufacturers from seeking patent settlement agreements.

On Tuesday, August 20th, CLSA welcomed a host of lawmakers, legislative staffers, and other key stakeholders to a first of its kind medical device showcase reception in Sacramento.